A phase I study of indoximod in patients with advanced malignancies

2016142 citationsJournal Articlediamond Open Access

Authors

Hatem Soliman · Moffitt Cancer Center

Susan Minton · Moffitt Cancer Center

Hyo S. Han · Moffitt Cancer Center

Roohi Ismail‐Khan · Moffitt Cancer Center

Anthony Neuger · Moffitt Cancer Center

Fatema Khambati · Moffitt Cancer Center

David Noyes ·

Abstract

Indoximod was safe at doses up to 2000 mg orally twice/day. Best response was stable disease >6 months in 5 patients. Induction of hypophysitis, increased tumor antigen autoantibodies and CRP levels were observed.

Topics & Keywords

Tryptophan and brain disorders Bipolar Disorder and Treatment Childhood Cancer Survivors' Quality of Life

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Oncotarget

Volume 7, Issue 16, pp. 22928-22938

DOI: 10.18632/oncotarget.8216

Field-Weighted Citation Impact: 8.00